Regulation - Pricing

Filter

Current filters:

Pricing

Popular Filters

176 to 200 of 321 results

UK's NICE initially negative on InterMune's Esbriet for idiopathic pulmonary fibrosis

30-11-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) said yesterday that…

BiotechnologyEsbrietEuropeInterMunePricingRegulationRespiratory and Pulmonary

New Zealand updates on Tracleer and sildenafil listing

21-11-2012

New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with…

ActelionArrow PharmaceuticalsAsia-PacificPharmaceuticalPricingRegulationRespiratory and PulmonarysildenafilTracleer

Australia to add Pfizer's Lyrica to PBS list; call for antibiotic research incentives

18-11-2012

Australia's Health Minister Tanya Plibersek on Friday announced the government's decision to subsidize…

Asia-PacificLyricaPfizerPharmaceuticalPricingRegulationResearch

Gilead HIV drugs Atripla and Truvada to be listed in New Zealand

13-11-2012

Following a consultation, New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval…

Anti-viralsAsia-PacificAtriplaBiotechnologyGilead SciencesPharmaceuticalPricingRegulationTruvada

Alcon's Nevanac accepted for NHS use in Scotland

12-11-2012

Ophthalmic specialist Alcon, a part of Swiss drug major Novartis (NOVN: VX), said yesterday that its…

AlconEuropeNevanacNovartisOphthalmicsPharmaceuticalPricingRegulation

UK's NICE revokes NHS use of Novartis' Xolair for asthma in children and adults

09-11-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in draft guidance…

EuropeNovartisPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

"India Pharma Inc" gearing up for the next level of growth

05-11-2012

Indian pharmaceutical companies will have to rethink business strategy in the light of several interventions…

Asia-PacificGenericsHealthcareMarkets & MarketingPharmaceuticalPricingProductionRegulation

New Zealand decision on proposal for various Novartis products

05-11-2012

Following a public consultation, New Zealand's Pharmaceutical Management Agency PHARMAC yesterday announced…

Asia-PacificNovartisPharmaceuticalPricingRegulation

UK's NICE plans to back NHS use of two breakthrough skin cancer treatments

01-11-2012

The UK's drugs watchdog the National Institute for Health and Clinical Excellence (NICE) this morning…

Bristol-Myers SquibbEuropeOncologyPharmaceuticalPricingRegulationRocheYervoyZelboraf

EMIG calls for greater clarity on value-based medicines from UK Parliamentary inquiry into NICE

31-10-2012

The UK Ethical Medicines Industry Group (EMIG) has welcomed the House of Commons Health Select Committee's…

BiotechnologyEuropePharmaceuticalPoliticsPricingRegulation

Access to many more medicines in Australia, as PBS list extended

28-10-2012

More than 110,000 Australians will benefit from better access to affordable medicines following the Australian…

Asia-PacificBayerEyleaMyforticNovartisPharmaceuticalPricingRegulation

Amgen's Xgeva gets NICE backing for bone metastasis

24-10-2012

New guidance published today (October 24) by the UK's drugs watchdog the National Institute for Health…

AmgenBiotechnologyEuropeOncologyPricingRegulationXgeva

New Zealand's PHARMAC decisions on Roche products

11-10-2012

PHARMAC, the pharmaceutical management agency in New Zealand, has made decisions on the proposal for…

Asia-PacificAvastinHypnovelMabTheraPharmaceuticalPricingRegulationRocheValcyte

UK's NICE draft guidance backs NHS use of Lucentis in DME

05-10-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in new draft guidance…

BiotechnologyEuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

Proposal in relation to Actelion's Tracleer in New Zealand

01-10-2012

New Zealand's national pharmaceuticals funding agency PHARMAC is seeking feedback on a proposal in relation…

ActelionAsia-PacificBiotechnologyPricingRegulationRespiratory and PulmonaryTracleer

Novartis criticizes system of public procurement tenders in Russia

28-09-2012

Amid the ever growing competition in the Russian pharmaceutical market, the world's largest pharmaceutical…

EuropeNovartisPharmaceuticalPricingRegulation

NICE final guidance backs NHS use of Boehringer Ingelheim's Actilyse

25-09-2012

In final guidance issued this morning (September 26), UK drugs watchdog the National Institute for Health…

ActilyseBoehringer IngelheimCardio-vascularEuropePharmaceuticalPricingRegulation

Scotland denies access to Roche skin cancer drug Zelboraf, but OKs Novartis' Gilenya

11-09-2012

Swiss drug major Roche (ROG SIX) says it is "extremely disappointed" that the Scottish Medicines Consortium…

EuropeGilenyaHealthcareNeurologicalNovartisOncologyPharmaceuticalPricingRegulationRocheZelboraf

UK NICE agrees to reconsider decision to deny NHS access to GSK's Benlysta

07-09-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) confirmed this…

Anti-Arthritics/RheumaticsBenlystaEuropeGlaxoSmithKlinePharmaceuticalPricingRare diseasesRegulation

A blip or stark reality? Pharma companies re-evaluate emerging markets

28-08-2012

Pharmaceutical companies, which have previously been allaying the growing fears and concerns of their…

FinancialGlobalMarkets & MarketingPharmaceuticalPricingRegulation

Europe's drug pricing sent askew by economic crash

22-08-2012

The European Union faced further fallout from the global financial crisis this year, and the region's…

EuropeHealthcarePharmaceuticalPricingRegulation

NICE says Roche's Avastin in breast cancer does not provide enough benefit to justify its cost

21-08-2012

The latest and final guidance from the UK's drug watchdog the National Institute for Health and Clinical…

AvastinBiotechnologyEuropeOncologyPharmaceuticalPricingRegulationRoche

AHF calls for Gilead's Quad HIV pill to be put on "prior authorization" status

19-08-2012

In what may be an unprecedented move on drug pricing and access, advocates from the AIDS Healthcare Foundation…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalPricingQuadRegulation

UK's NICE continues to back Amgen's Xgeva for most cancer patients with bone metastases

17-08-2012

In a final draft guidance issued today, (August 17), the National Institute for Health and Clinical Excellence…

AmgenBiotechnologyEuropePricingRegulationXgeva

176 to 200 of 321 results

Back to top